Potential Diagnostic Value of the Differential Expression of Histone H3 Variants between Low- and High-Grade Gliomas
Authors:
- Irati Hervás-CorpiónIrati Hervás-Corpión
- Andrea Gallardo-OrihuelaAndrea Gallardo-Orihuela
- Inmaculada Catalina-FernándezInmaculada Catalina-Fernández
- Irene Iglesias-LozanoIrene Iglesias-Lozano
- Olga Soto-TorresOlga Soto-Torres
- Noelia Geribaldi-DoldánNoelia Geribaldi-Doldán
- Samuel Domínguez-GarcíaSamuel Domínguez-García
- Nuria Luna-GarcíaNuria Luna-García
- Raquel Romero-GarcíaRaquel Romero-García
- Francisco Mora-LópezFrancisco Mora-López
- Marianela Iriarte-GaheteMarianela Iriarte-Gahete
- Jorge C. MoralesJorge C. Morales
Open Access
Abstract
Glioblastoma (GB) is the most aggressive form of glioma and is characterized by poor prognosis and high recurrence despite intensive clinical interventions. To retrieve the key factors underlying the high malignancy of GB with potential diagnosis utility, we combined the analysis of The Cancer Gene Atlas and the REMBRANDT datasets plus a molecular examination of our own collection of surgical tumor resections. We determined a net reduction in the levels of the non-canonical histone H3 variant H3.3 in GB compared to lower-grade astrocytomas and oligodendrogliomas with a concomitant increase in the levels of the canonical histone H3 variants H3.1/H3.2. This increase can be potentially useful in the clinical diagnosis of high-grade gliomas, as evidenced by an immunohistochemistry screening of our cohort and can be at least partially explained by the induction of multiple histone genes encoding these canonical forms. Moreover, GBs showing low bulk levels of the H3.1/H3.2 proteins were more transcriptionally similar to low-grade gliomas than GBs showing high levels of H3.1/H3.2. In conclusion, this study identifies an imbalanced ratio between the H3 variants associated with glioma malignancy and molecular patterns relevant to the biology of gliomas, and proposes the examination of the H3.3 and H3.1/H3.2 levels to further refine diagnosis of low- and high-grade gliomas in future studies.Keywords
Funding Information
- Instituto de Salud Carlos III (CP15/00180, PI16/00722, PI19/00125, CPII20/00025, PI15/01147, CM18/00043)
- Ministerio de Ciencia e Innovación (RTI2018-099908-B-C21)
This publication has 59 references indexed in Scilit:
- Personalized treatment strategies in glioblastoma: MGMT promoter methylation statusOncoTargets and Therapy, 2013
- Dynamics of Histone H3 Deposition In Vivo Reveal a Nucleosome Gap-Filling Mechanism for H3.3 to Maintain Chromatin IntegrityMolecular Cell, 2011
- Genomewide characterization of non-polyadenylated RNAsGenome Biology, 2011
- Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than HistologyCancer Research, 2009
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Use of within-array replicate spots for assessing differential expression in microarray experimentsBioinformatics, 2005
- H3 mRNA level as a new proliferative marker in astrocytomasBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- affy—analysis of Affymetrix GeneChip data at the probe levelBioinformatics, 2004